Samsung Bioepis Co., Ltd. requests that their press release NewsItemId: 20260505353718 “Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)” be killed.

The release was issued prematurely by Samsung Bioepis Co., Ltd.

The news release will be updated and redistributed in the near future, incorporating further information on SB27.

We are excited to announce preliminary results from the Phase 1 study for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development.